Precision targeting of STING: Challenges, innovations, and clinical outlook for cancer therapy

Public summary

* The STING agonists have yet to demonstrate durable clinical efficacy.

* Drug limitations, tumor heterogeneity, and immune suppression contribute to treatment resistance.

* Drug delivery, molecular design, and combination strategies offer promising clinical translation avenues.

* This review outlines the barriers to STING activation and the strategies for STING-targeted immunotherapy.

Abstract

The stimulator of interferon genes (STING) pathway plays a crucial role in immune responses and has emerged as a compelling target in cancer therapy. Despite promising preclinical studies, clinical trials of STING agonists have largely failed to deliver durable efficacy, with no agents progressing to phase III trials. This review examines the biological, pharmacological, and clinical barriers limiting STING pathway activation in cancer treatment. We discuss the inherent limitations of STING agonists as well as host-related resistance driven by tumor heterogeneity, immune suppression, and chronic STING activation. Mechanisms of acquired resistance, such as immune checkpoint upregulation and suppression of effector immune cells, are also reviewed. Recent advances in delivery platforms, small-molecule design, and combination treatment strategies offer promising paths forward. We highlight precision approaches based on human STING variants, epigenetic modulation, and biomarker-driven patient stratification to improve clinical outcomes. These insights underscore the need for refined, context-specific STING activation strategies to unlock the full therapeutic potential of this pathway in oncology.